Navegando por Autor "Oliveira, João Paulo Maia de"
Agora exibindo 1 - 4 de 4
- Resultados por página
- Opções de Ordenação
Dissertação Indicadores de transtornos de estresse pós-traumático em bombeiros militares(Universidade Federal do Rio Grande do Norte, 2013-05-29) Moura, Georgia de Oliveira; Alchieri, João Carlos; ; http://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4790051D1&dataRevisao=null; ; http://lattes.cnpq.br/1759088597796441; Calvo, Bernadino Fernández; ; http://lattes.cnpq.br/4082400623552153; Oliveira, João Paulo Maia de; ; http://lattes.cnpq.br/7719986496000598O presente estudo objetiva verificar a presença de indicadores de Transtorno de Estresse Pós-Traumático TEPT em Bombeiros Militares de dois estados do nordeste, visto que essa população lida com eventos traumáticos em seu cotidiano. Por ser um trabalho complexo que lhes demanda técnica e habilidades específicas para a situação, faz-se necessário e relevante, para a área de segurança pública, investigações num contexto da avaliação psicológica. Assim, foram avaliados 216 sujeitos com idades de 18 a 70 anos, do sexo masculino, de diferentes graduações, residentes e domiciliados nos Estados do Rio Grande do Norte e da Paraíba, vinculados à corporação do Corpo de Bombeiros Militares. Os instrumentos utilizados foram: formulário sociodemográfico, para caracterização da amostra, Inventário Clinico Multiaxial de Millon III (MCMI-III), Questionário de Saúde Geral de Golberg (QSG) e Mini Entrevista Neuropsiquiátrica Internacional (MINI). Os resultados demonstraram que o grupo com traços do TEPT apresentou diferenças significativas entre as médias com relação ao grupo sem os traços do transtorno. Os participantes apresentaram valores elevados para risco de transtorno ou mesmo a presença dele, no que se refere à saúde geral. Desenvolveram-se estudos quanto à obtenção de validade convergente da escala R Transtorno de Estresse Pós-Traumático do MCMI-III, cujos resultados apontaram o instrumento tem apropriada sensibilidade em distinguir pessoas que apresentam ou não o transtorno. Contudo, ainda são necessários estudos posteriores para verificação da avaliação e acompanhamento psicológico continuado desses profissionaisArtigo Moderators of ayahuasca’s biological antidepressant action(Frontiers Media SA, 2022-12) Sousa Júnior, Geovan Menezes de; Tavares, Vagner Deuel de Oliveira; Galvão, Ana Cecília de Menezes; Almeida, Raíssa Nóbrega de; Fontes, Fernanda Palhano Xavier de; Soares, Bruno Lobão; Freire, Fúlvio Aurélio de Morais; Nunes, Emerson Arcoverde; Oliveira, João Paulo Maia de; Perkins, Daniel; Sarris, Jerome; Araujo, Draulio Barros de; Coelho, Nicole Leite GalvãoIntroduction: The understanding of biological responses to psychedelics with antidepressant potential is imperative. Here we report how a set of acute parameters, namely emotional (depressive symptoms), cognitive (psychedelic experience), and physiological (salivary cortisol), recorded during an ayahuasca dosing session, modulated serum brain-derived neurotrophic factor (BDNF), serum cortisol (SC), serum interleukin 6 (IL-6), plasma C-reactive protein (CRP), and salivary cortisol awakening response (CAR). Methods: Results were analyzed 2 days after the psychedelic intervention (ayahuasca) versus placebo in both patients with treatment-resistant depression and healthy volunteers. These measures were assessed as part of a randomized double-blinded, placebo-controlled trial (n = 72). Results: Results revealed that larger reductions of depressive symptoms during the dosing session significantly moderated higher levels of SC in patients. Whereas lesser changes in salivary cortisol levels during the ayahuasca intervention were related to higher BDNF levels in patients with a larger clinical response in the reduction in depressive symptoms. No moderator was found for patient's CAR, IL-6, and CRP responses to ayahuasca and for all biomarker responses to ayahuasca in healthy controls and in the placebo group. Discussion: In summary, some specific emotional and physiological parameters during experimental ayahuasca session were revealed as critical moderators of the improvement of major depression biomarkers, mainly BDNF and SC two days after ayahuasca intake. These findings contribute to paving the way for future studies investigating the biological antidepressant response to psychedelic therapyArtigo Pathophysiology of major depression by clinical stages(Frontiers Media SA, 2021-08-05) Galvão, Ana Cecília de Menezes; Almeida, Raíssa Nobrega; Sousa Júnior, Geovan Menezes de; Miguel, Mario André Leocadio; Fontes, Fernanda Palhano Xavier de; Araujo, Draulio Barros de; Soares, Bruno Lobão; Oliveira, João Paulo Maia de; Nunes, Emerson Arcoverde; Hallak, Jaime Eduardo Cecilio; Schuch, Felipe Barreto; Sarris, Jerome; Galvão-Coelho, Nicole LeiteThe comprehension of the pathophysiology of the major depressive disorder (MDD) is essential to the strengthening of precision psychiatry. In order to determine the relationship between the pathophysiology of the MDD and its clinical progression, analyzed by severity of the depressive symptoms and sleep quality, we conducted a study assessing different peripheral molecular biomarkers, including the levels of plasma C-reactive protein (CRP), serum mature brain-derived neurotrophic factor (mBDNF), serum cortisol (SC), and salivary cortisol awakening response (CAR), of patients with MDD (n = 58) and a control group of healthy volunteers (n = 62). Patients with the first episode of MDD (n = 30) had significantly higher levels of CAR and SC than controls (n = 32) and similar levels of mBDNF of controls. Patients with treatment-resistant depression (TRD, n = 28) presented significantly lower levels of SC and CAR, and higher levels of mBDNF and CRP than controls (n = 30). An increased severity of depressive symptoms and worse sleep quality were correlated with levels low of SC and CAR, and with high levels of mBDNF. These results point out a strong relationship between the stages clinical of MDD and changes in a range of relevant biological markers. This can assist in the development of precision psychiatry and future research on the biological tests for depressionArtigo Targeting the NMDA receptor-nitric oxide-cyclic GMP pathway to develop non-dopaminergic antipsychotic medications for schizophrenia(Associação Brasileira de Psiquiatria, 2011-09) Soares, Bruno Lobão; Oliveira, João Paulo Maia de; Machado-de-Sousa, João Paulo; Baker, Glen B.; Dursun, Serdar; Hallak, Jaime E. C.Schizophrenia is a devastating disorder that occurs in about 1% of the population worldwide. For over 30 years, it has been considered to be the result of dysfunctional brain dopaminergic pathways. However, dopaminergic antipsychotic drugs have proven effective for only some of the symptoms found in schizophrenia patients. Recent evidence suggests that dopaminergic abnormalities may be secondary to dysfunctions in multi-neurotransmitter systems modulating dopamine. One of the key neurotransmitters thought to be involved in schizophrenia is glutamate, and there is strong support for the involvement of a hypoactivity of N-methyl-D-aspartate (NMDA) glutamate receptors in the pathogenesis of schizophrenia. However, research with NMDA receptor agonists for the treatment of schizophrenia has produced inconsistent results, which may be due to the development of rapid tolerance to these compounds secondary to down-regulation of NMDA receptors. Perhaps the development of drugs that act on targets downstream NMDA receptors, such as nitric oxide (NO), could avoid the problem of the down-regulation of these receptors.